HYPOTHESIS: Intratympanic (IT) application of betahistine diffuses to the inner ear after 15 minutes of exposure and exhibits no ototoxicity. BACKGROUND: Management of Menière disease involves oral treatment with betahistine; however, is mitigated by a delayed bioavailability (enteral resorption; first-pass effect). Topical IT administration might achieve higher intracochlear concentration.
✦ The floor
Discussion
Signed responses from readers of the wire.
No actionable change for clinical practice; this is an animal safety and diffusion study only, and intratympanic betahistine for Ménière disease requires human trials before any clinical use can be recommended.
If confirmed in humans, intratympanic betahistine delivery could offer a more targeted, potentially more effective route of administration for Ménière disease management compared to oral dosing.
- 01Animal study evaluated intratympanic (through-the-eardrum) delivery of betahistine for Ménière disease.
- 02Betahistine diffused to the inner ear within 15 minutes of intratympanic application.
- 03No ototoxicity (medication-related hearing damage) was observed in the animal model.
- 04Results support the safety profile needed to consider future human trials.
- 05Published in Otology & Neurotology (DOI: 10.1097/MAO.0000000000005004).
Intratympanic betahistine diffuses to the inner ear within 15 minutes of application.
studysupportedIntratympanic betahistine causes no ototoxicity in the animal model tested.
studysupported- PMID
- 42430787
- DOI
- 10.1097/MAO.0000000000005004.
- Journal
- Otology & Neurotology
- Publication type
- research_article
- Evidence level
- 4
- Population
- Animal model (species not specified in abstract) used to evaluate inner ear drug delivery
- Intervention
- Intratympanic application of betahistine
Primary outcomes
Safety of intratympanic betahistine (ototoxicity assessment); Diffusion of betahistine to the inner ear and time to diffusion